#Yervoy

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

A combination of two immunotherapy drugs may be more effective than the current standard treatment, chemotherapy.

More people treated with Opdivo plus Yervoy reached the 6.5-year survival mark than those treated with either drug alone.

A larger Phase II trial has been launched to evaluate the combination’s efficacy and safety.

The immunotherapy combo improved overall survival compared with chemotherapy.

Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.

The combination led to improved overall survival compared with chemotherapy.

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.

A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.

The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

Chelsea Dawson, an eight-year melanoma survivor, lives with her family in Roanoke, Virginia.

Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.